Bacterial beta-galactosidase (LacZ) (LacZ)

Bacterial beta-galactosidase, most notably the LacZ enzyme from Escherichia coli, is a glycoside hydrolase that catalyzes the hydrolysis of beta-galactosides into monosaccharides. Its primary biological role is the breakdown of lactose into glucose and galactose, serving as a critical energy-acquisition mechanism for bacteria [UniProt: P00722]. In clinical applications, this enzyme is a key component of Gene Directed Enzyme Prodrug Therapy (GDEPT), where it is targeted to tumor cells to convert non-toxic galactosyl-conjugated prodrugs into potent cytotoxic drugs, thereby localizing chemotherapy effects [PubMed: 11596900]. Additionally, bacterial-derived beta-galactosidases like tilactase are used as oral enzyme replacement therapies to treat lactose intolerance by assisting in the digestion of dietary lactose [StatPearls: Lactose Intolerance]. The enzyme is also an essential tool in molecular biology, functioning as a reporter gene to study gene expression and protein interactions through colorimetric assays [Wikipedia: Beta-galactosidase]. Despite its versatility, therapeutic use is challenged by the potential for immunogenic reactions against the bacterial protein and the risk of off-target prodrug activation by endogenous human galactosidases [PubMed: 11596900].

Other names

Beta-D-galactosidaseLactaseBeta-galBeta-D-galactoside galactohydrolase

Bacterial beta-galactosidase catalyzes the hydrolysis of beta-galactosides into monosaccharides, such as the conversion of lactose into glucose and galactose, through a double-displacement mechanism involving a covalent galactosyl-enzyme intermediate [UniProt: P00722]. In therapeutic applications like Gene Directed Enzyme Prodrug Therapy (GDEPT), the enzyme is expressed in target cells to cleave galactosyl-masking groups from prodrugs, thereby releasing active cytotoxic agents locally [PubMed: 11596900].